info@strategicmarketresearch.com
26, Broadway, Suite 934, New York , 10004
United States Flag  US: +1-315-636-4233    United Kingdom Flag  UK: +44-162-237-0614    Indian Flag  IN: +91-826-083-6500
smrlogonew
  • Home
  • About
    • Why SMR
    • Research Methodology
    • Media Coverage
    • Join Our Team
  • Reports
    • Aerospace and Defense
    • Agriculture
    • Automotive
    • Chemicals and Materials
    • Consumer Goods
    • Energy and Power
    • Equipment and Machinery
    • Food and Beverages
    • Healthcare
    • Information and Communication Technology
    • Semiconductor and Electronics
    • Manufacturing and Construction
  • Our Practices
    • Syndicated Research
    • Consulting Services
    • Custom Research
    • Full-time Engagement Model
  • Insights
    • Press Release
    • Blog
  • Contact
Home » Press Releases » Global Injectable Drug Delivery Market worth $1677.91 Bn by 2030

Global Injectable Drug Delivery Market worth $1677.91 Bn by 2030


Published Date: Mar-2022 | Report Format:Electronic (PDF)

The report" Injectable Drug Delivery" Market by Device Type (Convention Injectables, Pre-filled syringes, Auto-Injectors, Pen-Injectables, and Wearable), By Products (Freeze Dried Products, and Injectable Sterile Products), Applications (Hormonal Disorders, Auto-Immune Diseases, Oncology, Orphan/Rare Diseases, and Others), By End-User (Hospitals, Home Care Settings, and Others) - Global Forecast to 2030. "The Global Injectable Drug Delivery Market share was USD 550.97 Bn in 2020. It is predicted to reach USD 1677.91 Bn by 2030, representing a CAGR of 11.78 percent throughout the prevised period. Some of the most notable factors that are significantly driving the overall growth of the market worldwide are the continuous increase in the total number of chronic diseases, needle injuries, and the rise in the usage of injections. 

To know more about the report, Click on the link  https://www.strategicmarketresearch.com/market-report/injectable-drug-delivery-market

 

By Device Type, the ‘Convention Injectables ' segment held the most amount of share in 2020

Based on Device Type, the Injectable Drug Delivery industry worldwide has been broadly bifurcated into Convention Injectables, Pre-filled syringes, Auto-Injectors, Pen-Injectables, and Wearable. The “Convention Injectables” dominated the market comprehensively in 2020 with a steady CAGR value. The continuous rise in the total number of infectious diseases worldwide, the continuous rise in the number of sales of the traditional syringes due to an increase of hospital admissions, rise in the number of surgeries performed, and the introduction of many immunization programs across the globe are driving the growth of this segment.

 

By-Products, the ‘Injectable Sterile Products ' accounted for the largest share of the market in 2020

Based on Products, the Global Injectable Drug Delivery industry has been fragmented into Freeze-Dried Products and Injectable Sterile Products. The “Injectable Sterile Products” segment comprehensively held the highest share of nearly 67.38% of the entire market in 2020 due to its high storage capacity & quality assurance. These products are highly preferred by surgeons in hospitals for the treatment of various complex diseases. These injectable sterile are pathogen-free & thus are less prone to the risk of infections. All of these vital factors are propelling the overall growth of this segment extensively.

 

By Applications, the “Hormonal Disorders” segment held the most share of the market in 2020

Based on Applications, the Global Drug Delivery Injectables industry has been broadly segregated into Hormonal Disorders, Auto-Immune Diseases, Oncology, Orphan/Rare Diseases, and Others. The Hormonal Disorders segment dominated the market in 2020 with a steady CAGR. Factors such as thyroid problems, stress issues, eating disorders, lower sex drive, irregular periods, mood swings, and unexplained weight gain, are augmenting the overall market growth to a great extent.

 

 By End-User, the “Hospitals” segment held the maximum share of the entire market in 2020

Based on End-User, the Global Drug Delivery Injectables industry has been classified into Hospitals, Home Care Settings, and Others. The” Hospitals” segment dominated the market with the highest share with almost 62.17%. The rise of funding by the worldwide governments on healthcare sectors, and the longer duration of the patient’s stay back in the hospitals those of who are suffering from chronic or acute diseases are accelerating the overall growth of this segment efficiently.

 

Based on Regions, North America dominated the market with the highest share in 2020 (almost 194.89 billion) and a CAGR of 12.87% and will continue to be the most dominant region in the upcoming years. The higher rate of adoption of drug delivery technologies for cancer, diabetes, and other autoimmune disorders is fuelling the overall market growth in this region. As per ADA (American Diabetes Association), nearly 30.3 Mn people in the U.S were diagnosed with diabetes in 2018.

 

On the other hand, the Asia-Pacific region held the fastest growth rate in 2020 with a robust CAGR value owing to the increase in growth of healthcare sectors, rising patient pool, and a shift from conventional drug delivery injectables to the readily used injectables.

 

Some of the key vendors in the Global Injectable Drug Delivery Market include Teva Pharmaceuticals Industries Ltd, Pfizer Inc, Becton, Dickinson, and Company, Eli Lilly and Company, Gerresheimer, Ypsomed, Baxter International Inc, Schott AG, and B. Braun Melsungen

 

Recent Developments: -

  • On Dec 2nd, 2020, Becton, Dickinson, and Company declared that it has planned to invest approximately US$1.2 Bn in the Pre-Fillable Syringe Manufacturing Capacity in the next 4 years to come for the expansion & up-gradation of manufacturing capacity & technologies for the pre-fillable syringes (PFS) & advanced drug delivery systems (ADDS) across the six major global manufacturing locations & add some new manufacturing facilities in the European Union.

 

  • On Oct 5th, 2020, SCHOTT AG & Credence MedSystems joined hands together to form a Strategic Collaboration Agreement for making the Syringe Injections much safer for the sake of the benefit of the patients prevailing worldwide. Credence MedSystems, one of the leading innovators of injectable drug delivery technologies, had developed the Companion Safety Syringe System. This companion would allow the pharmaceutical manufacturers in providing critical usability & safety features to their respective end-users while integrating with the already existing syringe barrels including the primary packaging components.

Choose License Type



$0
$0
$0
Buy Now
"Click to avail the latest sample copy of the report"
Request Sample
"Probe before placing the order"
Pre-Order Enquiry
"Let's optimize your ROI by furnishing the best price"
Request Discount
"Want to curate the report according to your business needs:"
Ask for Customization

Trust Online

  • paypal.png
  • wiretransfers

Follow Us

  • facebook
  • twitter
  • instagram
  • linkedin

Contact Us

  • US: (+1) 315-636-4233
  • UK: (+44) 1622-370-614
  • IN: (+91) 826-083-6500
  • info@strategicmarketresearch.com
  • Strategic Market Research
    26, Broadway Suite 934, New York , 10004

Quick Link

  • Why SMR
  • Research Methodology
  • Media Coverage
  • Join Our Team
  • Press Release
  • Blog

Customer Support

  • FAQs
  • Contact
  • Terms of Use
  • Privacy Policy
  • Disclaimer Policy
  • Return Policy
Copyright © 2022 Strategic Market Research All rights reserved